Skip to content

Randomised Study Comparing Discharge 3 Days After Surgery to Home Within 24 Hours After Laparoscopic Hysterectomy.

Randomised Study Comparing Discharge 3 Days After Surgery to Home Within 24 Hours After Laparoscopic Hysterectomy.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02150200
Enrollment
44
Registered
2014-05-29
Start date
2014-05-31
Completion date
Unknown
Last updated
2014-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Women Who Undergo a Laparoscopic Hysterectomy for Benign Disease.

Brief summary

Hysterectomy is one of the most performed surgery in gynecologic surgery. Actually, 70 000 hysterectomies are performed each year in France. Laparoscopic surgery is in progression. The percentage of hysterectomies performed laparoscopically is increasing. The advantage of laparoscopy include fewer infections, less operative pain, faster recovery time and shorter hospital stay. In France, the average of hospital stay after laparoscopic hysterectomy reduced to 3-4 days. The study hypothesis is that a shorter postoperative stay does not decrease the quality of life of the patients. This study will compare the evolution of quality of life (with a questionnaire concerning measuring health related quality of life the Euroqol EQ-5D) of patients discharged after 3 days hospital stay to patients discharged the first day after a laparoscopic hysterectomy.

Interventions

OTHERshorter hospitalization stay
OTHERquestionnaires

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* age between 35 and 70. * affiliation to a social security system * signed informed consent form * disponibility of an responsible and valid accompanying person during 48 hours * home situation, less than one hour to go to an adapted structure of care * access to a phone

Exclusion criteria

* comorbidity which will automatically increase the period of hospital stay * contraindication in laparoscopy * difficulty to understand the protocol * no social security cover

Design outcomes

Primary

MeasureTime frameDescription
Quality of life assessed by the Euroqol EQ-5Dup to 30th days after the laparoscopic hysterectomy.Measure of quality of life with a questionnaire concerning health related quality of life (the Euroqol EQ-5D).The patients will complete the questionnaire at up to 30th days after the laparoscopic hysterectomy.

Secondary

MeasureTime frameDescription
Patient satisfactionPatient satisfaction assessed one month after intervention
Evaluation of pain by Visual Analog Scale for Pain and by analgesic drugs consumptionthe day of intervention, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days and 30 days after intervention
Anxiety assessment by the State trait anxiety inventory forme Y-Abefore intervention, the firt day, the second day, the third day after intervention, one week after intervention and one month after intervention.
Quality of life with assessed by the short SF-36 score (the 36 items Short Form Health Survey). in pre-operative time and 30 days after the hysterectomy.In pre-operative time and 30 days after the hysterectomy.
Comparison between a hospital stay of 3-4 days after laparoscopic hysterectomy costs and hospital stay of 1day after laparoscopic hysterectomy costs from the day of intervention until one month after intervention.each day from the date of intervention untill one month after intervention.The assessment will take into account any case of rehospitalization
Perioperative morbidityfrom intervention untill one month after intervention
Number of rehospitalizationone month after intervention
Patient recovery and discharge after intervention assessed by Post-Anaesthetic Discharge Scoring System (PADSS score).8 hours after laparoscopic surgery

Countries

France

Contacts

Primary ContactChérif YOUSSEF AZER AKLADIOS, Doctor
Cherif.YOUSSEF.AZER@chru-strasbourg.fr3 88 12 74 83

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026